XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator

Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378 million, net, in milestones plus mid-single digit to low teens royalties, net, from Organon

The Executive Leadership Team additions of Owen Hughes and Brad Sitko bring royalty investment and portfolio management expertise to increase shareholder value from XOMA’s future acquisitions

Royalty portfolio is maturing to the point where XOMA has potential for cash flows from two commercial assets in 2024

EMERYVILLE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, reported its full year 2022 financial results and provided an operational update on the Company’s actions to accelerate XOMA’s differentiated biotech royalty and milestone acquisition strategy.

“Since joining the Company in January, Brad Sitko and I have continually been impressed by the opportunities in front of XOMA.  After having a significant number of royalty and milestone acquisition conversations since January, we are making decisions thoughtfully and rapidly about the opportunities on which we want to transact.  We are assessing each potential opportunity with an eye to maximizing shareholder returns,” stated Owen Hughes, Executive Chairman of XOMA.

“With cash receipts from Vabysmo® (faricimab) and Day One’s public comments regarding filing a New Drug Application for tovorafenib in the first half of 2023, XOMA could be reporting incoming cash from two portfolio assets by the end of 2024.  Our economic interests in both these assets were acquired within the past two years.  In addition, we have learned from our partners’ public statements there also may be three assets entering Phase 3 development in 2023, which would further increase the value of XOMA’s portfolio.  Those are just a few examples of the progression within the more than 70 royalty and milestone assets in our portfolio.  With the potential incoming cash receipts from commercialized assets and anticipated milestone payments, we have the ability to accelerate our royalty acquisition strategy and continue to grow XOMA’s portfolio,” said Brad Sitko, Chief Investment Officer of XOMA.

Fourth Quarter and Full Year 2022 Financial Results

Revenues for the fourth quarter and year ended December 31, 2022, were $1.5 million and $6.0 million, respectively.  For the full year of 2022, XOMA’s reported revenues were related to milestone payments of $2.0 million from Rezolute, $0.8 million from Takeda, $0.8 million from Compugen, and $0.5 million from Sonnet.  Revenues in the fourth quarter and year ended December 31, 2021, were $35.9 million and $38.2 million, respectively.  For the full year of 2021, XOMA’s reported revenues included milestones of $35.0 million from Novartis, $0.5 million from Compugen, and $0.7 million from Janssen.

The Company’s research and development (R&D) expenses for the quarter and the full year of 2022 were $0.03 million and $0.2 million, respectively, compared to $0.04 million and $0.2 million in the corresponding periods of 2021.

General and administration (G&A) expenses were $7.6 million and $23.2 million for the fourth quarter and year-ended December 31, 2022, respectively.  G&A expenses were $5.5 million and $20.5 million for the corresponding periods of 2021.  The $2.7 million net increase in 2022, compared with 2021, was primarily due a $2.6 million increase in salaries and related expenses, including the $1.2 million Continuity Incentive accrued in connection with the retirement of Jim Neal, a $0.7 million increase in salaries and wages due to increased headcount and general salary increases, $0.4 million related to bonus payments to Mr. Neal pursuant to his amended employment agreement, and $0.1 million accrued in connection with the employee retention bonus.  Additionally, an increase in consulting and legal costs of $2.3 million contributed to the overall increase in 2022.  The totality of the increases in 2022 were partially offset by a $2.6 million reduction in stock-based compensation expense for stock options.

In the fourth quarter and full year of 2022, G&A expenses included $1.0 million and $3.6 million, respectively, in non-cash stock-based compensation expense, compared with $1.7 million and $6.2 million for the corresponding periods of 2021.  XOMA’s net cash used in operations in the fourth quarter of 2022 was $3.9 million and $12.9 million for the full year of 2022, compared with net cash provided by operations in the fourth quarter of 2021 of $30.7 million and $22.7 million for the full year of 2021.

Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million, respectively.  Net income for the fourth quarter of 2021 was $29.8 million and $15.8 million for the full year of 2021.

On December 31, 2022, XOMA had cash and cash equivalents of $57.8 million and no debt on its balance sheet.  On December 31, 2021, XOMA had cash and restricted cash of $95.4 million.  On January 17, 2023, the Company paid cash dividends on the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) equal to $0.53906 per share and cash dividends on the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) equal to $0.52344 per depositary share.  In February 2023, XOMA received a cash payment from Roche, representing the second commercial payment from XOMA’s 0.5% commercial interest in the sales of Vabysmo®.  The payment will be reflected in the Company’s condensed consolidated balance sheet as of March 31, 2023, as a reduction of short-term royalty and commercial payment receivables.

“The first year’s commercial performance of Vabysmo® has demonstrated the significant impact that even a small percentage of sales from a single multi-billion-dollar product can have on XOMA’s financial outlook.  Excluding any additional asset acquisitions, we believe incoming net cash of over $20 million from a combination of milestones that are expected this year together with anticipated royalties should cover our annual base operating and dividend expenses in 2023.  Given the nature of our milestone and royalty agreements, we expect cash flows will be uneven on a quarterly basis over the next few years.  This reflects the imprecise timing of when milestones occur and assets are commercialized.  Looking at 2024, the milestones and royalties we anticipate should continue to contribute significantly towards covering our base operating expenses and dividend obligations,” stated Tom Burns, Chief Financial Officer at XOMA.

About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.

Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA, the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, XOMA’s business forecast, the potential expansion and accelerated growth of XOMA’s portfolio, and the potential for this portfolio to generate sustained cashflows and positive returns over time.  In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions.  These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements.  These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic.  Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission.  Consider such risks carefully when considering XOMA's prospects.  Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.  XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except Vabysmo® (faricimab), are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.

XOMA Investor ContactXOMA Media Contact
Juliane SnowdenKathy Vincent
XOMA CorporationKV Consulting & Management
+1 646-438-9754+1 310-403-8951


(in thousands, except share and per share amounts)
 December 31,  December 31,
  2022   2021 
Current assets:   
Cash and cash equivalents $                  57,826  $                  93,328 
Restricted cash                                -                            2,049 
Short-term equity securities                            335                             774 
Trade and other receivables, net                                1                             209 
Short-term royalty and commercial payment receivables                        2,366                                 -   
Prepaid expenses and other current assets                           725                             613 
Total current assets                      61,253                        96,973 
Property and equipment, net                                7                                13 
Operating lease right-of-use assets                              29                             200 
Long-term royalty and commercial payment receivables                      63,683                        69,075 
Intangible assets, net                       15,150                                 -   
Other assets - long term                            260                             301 
Total assets$                140,382  $                166,562 
Current liabilities:   
Accounts payable$                        524  $                     1,072 
Accrued and other liabilities                        2,918                             525 
Income taxes payable                               -                                  91 
Contingent consideration under RPAs and CPPAs                              75                          8,075 
Operating lease liabilities                              34                             195 
Unearned revenue recognized under units-of-revenue method                        1,899                          1,641 
Preferred stock dividend accrual                         1,368                          1,368 
Total current liabilities                        6,818                        12,967 
Unearned revenue recognized under units-of-revenue method – long-term                        9,550                        11,685 
Long-term operating lease liabilities                               -                                  34 
Total liabilities                      16,368                        24,686 
Stockholders’ equity:   
Preferred Stock, $0.05 par value, 1,000,000 shares authorized:   
8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at December 31, 2022, and December 31, 2021                              49                                49 
8.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding at December 31, 2022, and December 31, 2021                              —                                — 
Convertible preferred stock, 5,003 issued and outstanding at December 31, 2022, and December 31, 2021                              —                                — 
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,454,025 and
11,315,263 shares issued and outstanding at December 31, 2022, and December 31, 2021, respectively
                              86                                85 
Additional paid-in capital                1,306,271                  1,307,030 
Accumulated deficit              (1,182,392)               (1,165,288)
Total stockholders’ equity                   124,014                     141,876 
Total liabilities and stockholders’ equity$                140,382  $                166,562 


(in thousands, except per share amounts)
 Three Months Ended December 31, Twelve Months Ended December 30,
  2022   2021   2022   2021 
   Revenue from contracts with customers$              850  $         35,424  $           4,150  $         36,518 
   Revenue recognized under units-of-revenue method                 636                   520                1,877                1,642 
          Total revenues              1,486              35,944                6,027              38,160 
Operating expenses:       
     Research and development                   28                     42                   153                   171 
     General and administrative              7,571                5,537              23,191              20,460 
     Amortization of intangible assets                   97                      -                       97                      -   
          Total operating expenses              7,696                5,579              23,441              20,631 
          (Loss) income from operations             (6,210)             30,365             (17,414)             17,529 
Other income (expense), net:       
          Interest expense                    -                        -                        -                    (461)
          Loss on extinguishment of debt                    -                        -                        -                    (300)
          Other income (expense), net                 219                  (430)                  295                  (879)
(Loss) income before income tax             (5,991)             29,935             (17,119)             15,889 
Income tax benefit (expense)                   15                    (91)                    15                    (91)
Net (loss) income and comprehensive (loss) income$          (5,976) $         29,844  $        (17,104) $         15,798 
Net (loss) income and comprehensive (loss) income (attributable to) available to common stockholders, basic$          (7,344) $         19,744  $        (22,576) $           7,787 
Net (loss) income and comprehensive (loss) income (attributable to) available to common stockholders, diluted$          (7,344) $         20,136  $        (22,576) $           7,968 
Basic net (loss) income per share (attributable to) available to common stockholders$            (0.64) $             1.75  $            (1.98) $             0.69 
Diluted net (loss) income per share  (attributable to) available to common stockholders$            (0.64) $             1.67  $            (1.98) $             0.65 
Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders            11,452              11,313              11,413              11,288 
Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders            11,452              12,079              11,413              12,192 


(in thousands)
 Year Ended December 31, 
 2022     2021 
Cash flows from operating activities:     
Net (loss) income$          (17,104) $          15,798 
Adjustments to reconcile net (loss) income to net cash (used in) provided by
operating activities:
Stock-based compensation expense              3,608               6,195 
Common stock contribution to 401(k)                   85                    90 
Depreciation                     7                      7 
Amortization of debt issuance costs, debt discount and final payment on debt                    —                  200 
Loss on extinguishment of debt                    —                  300 
Reduction of contingent NIH refund liability                    —                (105)
Non-cash lease expense                 170                  160 
Change in fair value of equity securities                 439                  919 
 Amortization of intangible assets                    97                    — 
Changes in assets and liabilities:     
Trade and other receivables, net                 208                    54 
Income tax receivable                    —               1,526 
Prepaid expenses and other assets                  (71)               (169)
Accounts payable and accrued liabilities              1,845                  765 
Income taxes payable                  (91)                   91 
Operating lease liabilities                (195)               (179)
Unearned revenue recognized under units-of-revenue method             (1,877)            (1,642)
Contingent NIH refund liability                    —             (1,305)
Other liabilities                    —                  (27)
Net cash (used in) provided by operating activities           (12,879)            22,678 
Cash flows from investing activities:     
Payments of consideration under RPAs and CPPAs             (8,000)          (26,500)
Receipts under RPAs and CPPAs               3,026                    — 
Payment for IP acquired under the ObsEva IP Acquisition Agreement           (15,247)                   — 
Net cash used in investing activities           (20,221)          (26,500)
Cash flows from financing activities:     
Proceeds from issuance of preferred stock                    —             40,000 
Payment of preferred stock dividends              (5,472)            (3,499)
Payment of preferred and common stock issuance costs                    —             (3,385)
Proceeds from exercise of options and other share-based compensation              2,419               1,584 
Taxes paid related to net share settlement of equity awards             (1,398)               (488)
Principal payments – debt                    —             (4,250)
Net cash (used in) provided by financing activities             (4,451)            12,835 
Net (decrease) increase in cash, cash equivalents and restricted cash            (37,551)              9,013 
Cash and restricted cash at the beginning of the period            95,377             86,364 
Cash, cash equivalents and restricted cash at the end of the period$           57,826  $          95,377 
Supplemental Cash Flow Information:       
Cash paid for taxes $                  76  $                 — 
Cash paid for interest$                   —  $               311 
Non-cash investing and financing activities:          
Preferred stock dividend accrual$             1,368  $            1,368 
Accrued transaction costs in connection with ObsEva IP Acquisition$122  $                 —